Suppr超能文献

肠球菌性心内膜炎的治疗新进展?

What's New in the Treatment of Enterococcal Endocarditis?

机构信息

Division of Infectious Diseases, Department of Internal Medicine, University of Texas Medical School at Houston, Houston, TX, USA.

出版信息

Curr Infect Dis Rep. 2014 Oct;16(10):431. doi: 10.1007/s11908-014-0431-z.

Abstract

Enterococcus spp. are among the common pathogens causing infective endocarditis (IE). Despite major medical advances and new potent antimicrobial agents, the mortality has not significantly improved for several decades. The usual lack of bactericidal activity of penicillin or ampicillin, the toxicity from the combination of penicillin plus aminoglycosides, and the increased reports of high-level resistance to aminoglycosides have led to the exploration of other regimens for treatment of Enterococcus faecalis IE. As an example, ampicillin plus ceftriaxone is now a well-recognized regimen for this organism. However, the emerging of new drug resistances in Enterococcus faecium dramatically reduces the therapeutic alternatives for this organism in IE which continues to be an immense challenge for clinicians even with the availability of newer antimicrobial agents. This article summarizes the current treatment options for enterococcal endocarditis and reviews of recent publications on the topic.

摘要

肠球菌属是引起感染性心内膜炎(IE)的常见病原体之一。尽管在医学上取得了重大进展,并且出现了新的强效抗菌药物,但几十年来死亡率并没有显著改善。青霉素或氨苄西林通常缺乏杀菌活性,青霉素加氨基糖苷类药物联合使用会产生毒性,并且氨基糖苷类药物的高水平耐药性报告越来越多,这导致了人们探索治疗粪肠球菌 IE 的其他方案。例如,氨苄西林加头孢曲松现在是治疗这种病原体的公认方案。然而,屎肠球菌中新的耐药性的出现极大地减少了这种病原体在 IE 中的治疗选择,即使有新的抗菌药物,IE 对临床医生来说仍然是一个巨大的挑战。本文总结了肠球菌性心内膜炎的当前治疗选择,并对该主题的最新出版物进行了回顾。

相似文献

1
What's New in the Treatment of Enterococcal Endocarditis?
Curr Infect Dis Rep. 2014 Oct;16(10):431. doi: 10.1007/s11908-014-0431-z.
2
Outpatient parenteral antimicrobial therapy in Enterococcus faecalis infective endocarditis.
J Clin Pharm Ther. 2018 Apr;43(2):220-223. doi: 10.1111/jcpt.12635. Epub 2017 Oct 13.
3
Enterococcal endocarditis revisited.
Future Microbiol. 2015;10(7):1215-40. doi: 10.2217/fmb.15.46. Epub 2015 Jun 29.
4
Enterococcal endocarditis: can we win the war?
Curr Infect Dis Rep. 2012 Aug;14(4):339-49. doi: 10.1007/s11908-012-0270-8.
6
Treatment of Infective Endocarditis: A Continuing Challenge.
Antibiotics (Basel). 2023 Apr 4;12(4):704. doi: 10.3390/antibiotics12040704.
7
8
A surveillance of high-level gentamicin-resistant enterococcal bacteremia.
Kansenshogaku Zasshi. 2012 Mar;86(2 Suppl 4):27-8.
10
Ampicillin Plus Ceftriaxone Regimen against Endocarditis: A Literature Review.
J Clin Med. 2021 Oct 6;10(19):4594. doi: 10.3390/jcm10194594.

引用本文的文献

1
Isolated Pulmonary Valve Endocarditis Caused by -Facing the Unpredictable.
Antibiotics (Basel). 2025 Feb 21;14(3):220. doi: 10.3390/antibiotics14030220.
5
Measuring Epidemiologic Effects of Enterococcal Bacteremia and Outcomes From a Nationwide Inpatient Sample Database.
Cureus. 2022 Jul 31;14(7):e27516. doi: 10.7759/cureus.27516. eCollection 2022 Jul.
6
Infective Endocarditis in High-Income Countries.
Metabolites. 2022 Jul 25;12(8):682. doi: 10.3390/metabo12080682.
8
sp. nov., isolated from the wax moth .
Int J Syst Evol Microbiol. 2021 Dec;71(12). doi: 10.1099/ijsem.0.005168.
9
A sampling survey of enterococci within pasteurized, fermented dairy products and their virulence and antibiotic resistance properties.
PLoS One. 2021 Jul 15;16(7):e0254390. doi: 10.1371/journal.pone.0254390. eCollection 2021.

本文引用的文献

1
Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium.
Antimicrob Agents Chemother. 2014;58(3):1494-500. doi: 10.1128/AAC.02274-13. Epub 2013 Dec 23.
2
Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States.
Antimicrob Agents Chemother. 2014;58(2):1243-7. doi: 10.1128/AAC.02112-13. Epub 2013 Dec 9.
3
Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia.
Antimicrob Agents Chemother. 2014;58(2):734-9. doi: 10.1128/AAC.01289-13. Epub 2013 Nov 18.
5
High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis.
Antimicrob Agents Chemother. 2013 Dec;57(12):6213-22. doi: 10.1128/AAC.01563-13. Epub 2013 Sep 30.
7
A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis.
J Antimicrob Chemother. 2013 Dec;68(12):2921-6. doi: 10.1093/jac/dkt294. Epub 2013 Aug 8.
8
Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections.
Antimicrob Agents Chemother. 2013 Oct;57(10):5013-8. doi: 10.1128/AAC.00714-13. Epub 2013 Jul 29.
9
Multicenter study of high-dose daptomycin for treatment of enterococcal infections.
Antimicrob Agents Chemother. 2013 Sep;57(9):4190-6. doi: 10.1128/AAC.00526-13. Epub 2013 Jun 17.
10
Treatment of high-level gentamicin-resistant Enterococcus faecalis endocarditis with daptomycin plus ceftaroline.
Antimicrob Agents Chemother. 2013 Aug;57(8):4042-5. doi: 10.1128/AAC.02481-12. Epub 2013 May 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验